Develops drugs for endocrine and neurological diseases.
Jun 2026Revenue $335M/yrExpenses $299M/yr
Reached break-even Aug 2025
Figures by year
When did Xeris Biopharma Holdings become profitable?
Its revenue passed its expenses in Aug 2025. In the 12 months to Jun 2026, revenue was $335M and expenses $299M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $292M | $267M | $24.9M |
| Dec 2024 | $203M | $237M | −$33.6M |
| Dec 2023 | $164M | $208M | −$44.0M |
| Dec 2022 | $110M | $192M | −$81.9M |
| Dec 2021 | $49.6M | $165M | −$115M |
| Dec 2020 | $20.2M | $104M | −$83.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.